Diagnosis and management of stage I/II melanomaLAMB, Lynne A; HALPERN, Allan C; HWU, Wen-Jen et al.Seminars in oncology nursing. 2003, Vol 19, Num 1, pp 22-31, issn 0749-2081, 10 p.Article

Dose-Dense Temozolomide Regimens: Antitumor Activity, Toxicity, and Immunomodulatory EffectsNEYNS, Bart; TOSONI, Alicia; HWU, Wen-Jen et al.Cancer. 2010, Vol 116, Num 12, pp 2868-2877, issn 0008-543X, 10 p.Article

Eruptive melanotic macules and papules associated with adenocarcinomaBUSAM, Klaus J; SACHS, Dana L; COLT, Daniel G et al.Journal of cutaneous pathology. 2003, Vol 30, Num 7, pp 463-469, issn 0303-6987, 7 p.Article

Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 gangliosideCHAPMAN, Paul B; WU, Dianna; RAGUPATHI, Govind et al.Clinical cancer research. 2004, Vol 10, Num 14, pp 4717-4723, issn 1078-0432, 7 p.Article

Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the Brain : High rate of thromboembolic events (CALGB 500102)KROWN, Susan E; NIEDZWIECKI, Donna; HWU, Wen-Jen et al.Cancer. 2006, Vol 107, Num 8, pp 1883-1890, issn 0008-543X, 8 p.Article

A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 gangliosideCHAPMAN, Paul B; WILLIAMS, Linda; SALIBI, Nadia et al.Vaccine. 2004, Vol 22, Num 21-22, pp 2904-2909, issn 0264-410X, 6 p.Article

Prognostic Factors for Survival in Melanoma Patients With Brain MetastasesDAVIES, Michael A; PING LIU; MCLNTYRE, Susan et al.Cancer. 2011, Vol 117, Num 8, pp 1687-1696, issn 0008-543X, 10 p.Article

Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic MelanomaDAVIES, Michael A; FOX, Patricia S; SHA HUANG et al.Clinical cancer research (Print). 2012, Vol 18, Num 4, pp 1120-1128, issn 1078-0432, 9 p.Article

Safety and Activity of Anti―PD-L1 Antibody in Patients with Advanced CancerBRAHMER, Julie R; TYKODI, Scott S; PITOT, Henry C et al.The New England journal of medicine. 2012, Vol 366, Num 26, pp 2455-2465, issn 0028-4793, 11 p.Article

Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in MelanomaHAMID, Omid; ROBERT, Caroline; DRONCA, Roxana et al.The New England journal of medicine. 2013, Vol 369, Num 2, pp 134-144, issn 0028-4793, 11 p.Article

PET/CT in the Management of Patients With Stage IIIC and IV Metastatic Melanoma Considered Candidates for Surgery: Evaluation of the Additive Value After Conventional ImagingBRONSTEIN, Yulia; NG, Chaan S; ROHREN, Eric et al.American journal of roentgenology (1976). 2012, Vol 198, Num 4, pp 902-908, issn 0361-803X, 7 p.Article

Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma PatientsRADVANYI, Laszlo G; BERNATCHEZ, Chantale; GLASS, Michelle et al.Clinical cancer research (Print). 2012, Vol 18, Num 24, pp 6758-6770, issn 1078-0432, 13 p.Article

Phase II study of temozolomide plus pegylated interferon-α-2b for metastatic melanomaHWU, Wen-Jen; PANAGEAS, Katherine S; HOUGHTON, Alan N et al.Cancer. 2006, Vol 106, Num 11, pp 2445-2451, issn 0008-543X, 7 p.Article

Temozolomide plus thalidomide in patients with brain metastases from melanoma : A phase II studyHWU, Wen-Jen; LIS, Eric; WOLCHOK, Jedd D et al.Cancer. 2005, Vol 103, Num 12, pp 2590-2597, issn 0008-543X, 8 p.Article

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialROBERT, Caroline; RIBAS, Antoni; PATNAIK, Amita et al.Lancet (British edition). 2014, Vol 384, Num 9948, pp 1109-1117, issn 0140-6736, 9 p.Article

Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanomaKIM, Kevin B; HWU, Wen-Jen; PAPADOPOULOS, Nicholas E et al.Cancer chemotherapy and pharmacology. 2009, Vol 64, Num 1, pp 161-167, issn 0344-5704, 7 p.Article

Randomized trial of an allogeneic Melanoma lysate vaccine with low-dose interferon alfa-2b compared with high-dose interferon alfa-2b for resected stage III cutaneous melanomaMITCHELL, Malcolm S; ABRAMS, Judith; JAKOWATZ, James G et al.Journal of clinical oncology. 2007, Vol 25, Num 15, pp 2078-2085, issn 0732-183X, 8 p.Article

Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21RAGUPATHI, Govind; LIVINGSTON, Philip O; HOOD, Chandra et al.Clinical cancer research. 2003, Vol 9, Num 14, pp 5214-5220, issn 1078-0432, 7 p.Article

Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)PATEL, Poulam M; SUCIU, Stefan; BECKER, Juergen et al.European journal of cancer (1990). 2011, Vol 47, Num 10, pp 1476-1483, issn 0959-8049, 8 p.Article

Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanomaHWU, Wen-Jen; KROWN, Susan E; LIVINGSTON, Philip O et al.Journal of clinical oncology. 2003, Vol 21, Num 17, pp 3351-3356, issn 0732-183X, 6 p.Article

T-Cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201⁺ melanoma patients: Randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvantsSCHAED, Susanne G; KLIMEK, Virginia M; CHAPMAN, Paul B et al.Clinical cancer research. 2002, Vol 8, Num 5, pp 967-972, issn 1078-0432Article

Temozolomide plus thalidomide in Patients with advanced melanoma: Results of a dose-finding trialHWU, Wen-Jen; KROWN, Susan E; PANAGEAS, Katherine S et al.Journal of clinical oncology. 2002, Vol 20, Num 11, pp 2610-2615, issn 0732-183XArticle